Table 1 Main characteristics of the included studies
Study ID | Mean age (years) | Country origin | Subjects, number (NS/HS) | Female (%) | Centre | ICUs | Disease types | Follow up (days) | Heparin concentration (IU/ml) | Heparin volume (ml) |
|---|---|---|---|---|---|---|---|---|---|---|
Rabe 2002 [13] | 59.25 | Germany | 33/33 | 63.64 | S | Y | Multi-disease | 20 | 5000 | 0.5 |
Kaneko 2004 [28] | 68.43 | Japan | 26/22 | 50.00 | S | N | Nephropathy | 48 | 1000 | 2 |
Pumarola 2007 [6] | 52.27 | Spain | 57/38 | 31.60 | M | Y | Multi-disease | 3 | 100 | 5 |
Bowers 2008 [32] | 54.36 | USA | 50/52 | 50.00 | S | N | Multi-disease | 10.3 | 100 | 3 |
Schallom 2012 [2] | 58.69 | USA | 150/145 | 48.81 | S | Y | Multi-disease | 14 | 10 | 3 |
Goossens 2013 [26] | 55.81 | Belgium | 404/398 | 65.34 | S | N | Cancer patients | 180 | 100 | 3 |
Beigi 2014 [29] | 63.1 | Iran | 49/47 | 45.83 | S | N | Multi-disease | 1 | 100 | … |
Lyons 2014 [31] | 52 | USA | 28/30 | 40 | H | N | Multi-disease | 23 | 10 | 5 |
Lyons 2014 [31] | 52 | USA | 28/32 | 40 | H | N | Multi-disease | 23 | 100 | 3 |
Molin 2015 [27] | 62.69 | Italy | 203/212 | 53.49 | M | N | Cancer patients | 400 | 50 | 5 |
Ziyaeifard 2015 [30] | 51.6 | Iran | 50/50 | 31.00 | S | Y | Cardiac surgery | 3 | 10 | 5 |